Actavia Life Sciences, Inc.
RASP
$0.004
-$0.0285-87.69%
Weiss Ratings | RASP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Very Weak | |||
Risk Index | Very Weak | |||
Risk Grade | E+ | |||
Reward Grade | E | |||
Rating Factors | RASP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Fair | |||
Efficiency Index | Very Weak | |||
Solvency Index | Very Weak | |||
Total Return Index | Very Weak | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | RASP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Beta | -1.79 | |||
Price History | RASP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | 0.00% | |||
30-Day Total Return | 0.00% | |||
60-Day Total Return | 0.00% | |||
90-Day Total Return | 0.00% | |||
Year to Date Total Return | 0.00% | |||
1-Year Total Return | -48.05% | |||
2-Year Total Return | -91.75% | |||
3-Year Total Return | -86.67% | |||
5-Year Total Return | -86.67% | |||
52-Week High % Change | -89.74% | |||
52-Week Low % Change | 150.00% | |||
Price | RASP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $0.04 | |||
52-Week Low Price | $0.00 | |||
52-Week Low Price (Date) | Jun 21, 2024 | |||
52-Week High Price (Date) | May 15, 2024 | |||
Valuation | RASP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 3.09M | |||
Enterprise Value | 3.39M | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | 0.00 | |||
Earnings Per Share Growth | -85.90% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | -- | |||
Price/Book (Q) | -1.43 | |||
Enterprise Value/Revenue (TTM) | -- | |||
Price | $0.00 | |||
Enterprise Value/EBITDA (TTM) | -- | |||
Enterprise Value/EBIT | -9.82 | |||
Market Cap Category | Nano Cap | |||
Dividends and Shares | RASP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 771.81M | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | RASP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 646 396 4087 | |||
Address | 5 Penn Plaza New York, NY 10001 | |||
Website | www.rasna.com | |||
Country | United States | |||
Year Founded | 2013 | |||
Profitability | RASP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | -- | |||
Profit Margin | -- | |||
Management Effectiveness | RASP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | -427.65% | |||
Return on Equity | -- | |||
Income Statement | RASP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | -- | |||
Total Revenue (TTM) | -- | |||
Revenue Per Share | -- | |||
Gross Profit (TTM) | -- | |||
EBITDA (TTM) | -- | |||
EBIT (TTM) | -345.20K | |||
Net Income (TTM) | -406.60K | |||
Net Income Avl. to Common (TTM) | -406.60K | |||
Total Revenue Growth (Q YOY) | -- | |||
Earnings Growth (Q YOY) | 97.69% | |||
EPS Diluted (TTM) | 0.00 | |||
EPS Diluted Growth (Q YOY) | 98.57% | |||
Balance Sheet | RASP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 1.40K | |||
Cash Per Share (Q) | $0.00 | |||
Total Current Assets (Q) | 48.60K | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | -2.18M | |||
Current Ratio (Q) | 0.022 | |||
Book Value Per Share (Q) | $0.00 | |||
Total Assets (Q) | 48.60K | |||
Total Current Liabilities (Q) | 2.23M | |||
Total Debt (Q) | 304.00K | |||
Total Liabilities (Q) | 2.23M | |||
Total Common Equity (Q) | -2.18M | |||
Cash Flow | RASP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | -- | |||
Cash from Financing (TTM) | 65.70K | |||
Net Change in Cash (TTM) | -800.00 | |||
Levered Free Cash Flow (TTM) | 6.90K | |||
Cash from Operations (TTM) | -66.40K | |||